(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2013 (13.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/084148 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/IB2012/056950

(22) International Filing Date:
4 December 2012 (04.12.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/566,905 5 December 2011 (05.12.2011) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors: **ELIS, Winfried**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE). **ETTENBERG, Seth**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **GARNER, Andrew Paul**; Novartis Institutes For Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **KUNZ, Christian Carsten Silvester**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE). **SEITZ, Tobias**; Morphosys Ag, Lena-Christ-Strasse 48, 82152 Planegg (DE).

(74) Agent: **SAGOO, Jasbir**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

[Continued on next page]

WO 2013/084148 A2

(54) Title: ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN II OF HER3

Figure 1



(57) Abstract: The present invention relates to antibodies or fragments thereof that target an epitope of a HER3 receptor residing in domain 2 of the HER3 receptor to block both ligand-dependent and ligand-independent signal transduction and tumor growth; and compositions and methods of use thereof.

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*